Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Anji Li, Shuai Sun, Tao Song, Xi Li, Wen Cheng, Ruipin Yao, Danying Zhang, Zailong Cai, Jie Zhang, Dongxia Zhai & Chaoqin Yu. (2018) Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. OncoTargets and Therapy 11, pages 3705-3711.
Read now
Read now
Marie Robert, Jean-Sébastien Frenel, Carole Gourmelon, Anne Patsouris, Paule Augereau & Mario Campone. (2017) Olaparib for the treatment of breast cancer. Expert Opinion on Investigational Drugs 26:6, pages 751-759.
Read now
Read now
Yun-Chun Zhao, Li Zhang, Shi-Sen Feng, Lu Hong, Hai-Li Zheng, Li-Li Chen, Xiao-Ling Zheng, Yi-Qing Ye, Meng-Dan Zhao, Wen-Xi Wang & Cai-Hong Zheng. (2016) Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome. International Journal of Nanomedicine 11, pages 5485-5496.
Read now
Read now
Articles from other publishers (8)
Wenhui Li, Di Shao, Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong, Fengming Guo, Zhe Wang & Mingzhi Ye. (2019) Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. Journal of Ovarian Research 12:1.
Crossref
Crossref
Lawrence B. Mensah, Stephen W. Morton, Jiahe Li, Haihua Xiao, Mohiuddin A. Quadir, Kevin M. Elias, Emily Penn, Aysen K. Richson, Paiman Peter Ghoroghchian, Joyce Liu & Paula T. Hammond. (2019) Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer. Bioengineering & Translational Medicine 4:2.
Crossref
Crossref
Renata A. Tassi, Paola Todeschini, Eric R. Siegel, Stefano Calza, Paolo Cappella, Laura Ardighieri, Moris Cadei, Mattia Bugatti, Chiara Romani, Elisabetta Bandiera, Laura Zanotti, Laura Tassone, Donatella Guarino, Concetta Santonocito, Ettore D. Capoluongo, Luca Beltrame, Eugenio Erba, Sergio Marchini, Maurizio D’Incalci, Carla Donzelli, Alessandro D. Santin, Sergio Pecorelli, Enrico Sartori, Eliana Bignotti, Franco Odicino & Antonella Ravaggi. (2017) FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal of Experimental & Clinical Cancer Research 36:1.
Crossref
Crossref
Paul Lesueur, François Chevalier, Jean-Baptiste Austry, Waisse Waissi, Hélène Burckel, Georges Noël, Jean-Louis Habrand, Yannick Saintigny & Florence Joly. (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8:40, pages 69105-69124.
Crossref
Crossref
Silvia R. Graziani, Carolina G. Vital, Aleksandra T. Morikawa, Brigitte M. Van Eyll, Hezio J. Fernandes Junior, Roberto Kalil Filho & Raul C. Maranhão. (2017) Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Medical Oncology 34:9.
Crossref
Crossref
Chandan Kumar, Nidhi Rani, Palanisamy Thanga Velan Lakshmi & Annamalai Arunachalam. (2017) A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. Future Medicinal Chemistry 9:1, pages 37-60.
Crossref
Crossref
Qianying Zhao, Jiaxin Yang, Lei LiDongyan Cao, Mei YuKeng Shen. (2017) Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Journal of Gynecologic Oncology 28:4.
Crossref
Crossref
Jennifer McLachlan, Angela George & Susana Banerjee. (2016) The Current Status of PARP Inhibitors in Ovarian Cancer. Tumori Journal 102:5, pages 433-440.
Crossref
Crossref